NIAID grants University of Maryland team $14.4M for HIV vax work

research

As it works to advance an HIV vaccine candidate, the University of Maryland’s Institute of Human Virology (IHV) this week received some big-name backing. The National Institute of Allergy and Infectious Diseases (NIAID) approved a $14.4 million grant for the team--led by veteran HIV researcher Dr. Robert Gallo--to continue its work toward creating an effective HIV vaccine.

The influx follows the group’s move into clinical trials last fall for its full-length single chain HIV vaccine prospect, a candidate designed to elicit protection “across the spectrum HIV-1 strains,” according to an IHV release. The researchers hope the candidate will serve as a system to inform all HIV vaccine design.

Gallo, whose group co-discovered HIV as the cause of AIDS decades ago, said the NIAID and other funding sources--including the Bill & Melinda Gates foundation--are “critical partners” in efforts to solve the “complex scientific challenge” of creating a durable vaccine against the virus.

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

But Maryland's IHV is far from alone in its R&D efforts, and it isn’t alone in winning NIAID support. In June, University of Massachusetts researchers won a $17.3 million grant from NIAID to develop and manufacture a prime-boost candidate for a midstage trial. The following month, a Texas Biomed team secured $23 million to explore an approach that will utilize three lines of defense for protection.

Those grants followed an announcement by the NIH that it’s launching a large-scale Phase IIb/III HIV vaccine trial in South Africa later this year. It’ll test HVTN 100--made up of one experimental vaccine each supplied by Sanofi Pasteur and GlaxoSmithKline--in 5,400 HIV-uninfected men and women with 5 injections over one year.

Other commitments to the field include Aelix Therapeutics, which launched with $12.7 million in January, and a €23 million public-private partnership launched last year by the European Commission.

- here's the release

Related Articles:
University of Maryland HIV vaccine candidate enters human trials
NIH to launch large-scale HIV vaccine trial in South Africa
European Commission launches €23M HIV vaccine research initiative
UMass team nabs $17M from NIAID to produce HIV vaccine

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.